Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia

Urology

Volumn 51, Issue 6, 1998, Pages 892-900

  Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; URINE FLOW RATE; UROFLOWMETRY; VERTIGO;

EID: 0032100513     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00126-5     Document Type: Article

References (21)

1. Lepor H. Medical therapy for benign prostatic hyperplasia. Urology. 42:1993;483-501.
2. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 22:1995;375-386.
3. Caine M., Perlberg S., Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 50:1978;551-554.
4. Abrams P.H., Shah P.J., Stone R., et al. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol. 54:1982;527-530.
5. Chapple C.R. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia rationale and clinical experience . Eur Urol. 29:1996;129-144.
6. Fawzy A., Braun K., Lewis G.P., et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients a multicenter study . J Urol. 154:1995;105-109.
7. Gillenwater J.Y., Conn R.L., Chrysant S.G., et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension a double-blind, placebo-controlled, dose-response multicenter study . J Urol. 154:1995;110-115.
8. Lepor H., Auerbach S., Puras-Baez A., et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 148:1992;1467-1474.
9. McKiernan J.M., Lowe F.C. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J. 90:1997;509-513.
10. Lowe F.C. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia a combined analysis . Urology. 44:1994;46-51.
11. Lepor H., Tang R., Kobayashi S., et al. Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol. 154:1995;2096-2099.
12. Andersson K.E., Lepor H., Wyllie M.G. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 30:1997;202-215.
13. 1C subtype. J Pharmacol Exp Ther. 45:1994;703-708.
14. Lepor H. Natural history, evaluation, and nonsurgical management of benign prostatic hyperplasia. Walsh P.C., Vaughan E.D. Jr, Retik A.B., et al. Campbell's Urology. 1997;1453-1477 WB Saunders, Philadelphia.
15. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
16. Lepor H. Prostate selectivity of alpha-blockers from receptor biology to clinical medicine . Eur Urol. 29:(suppl 1):1996;12-16.
17. Milam D, Oesterling JE, Roehrborn CG, et al, for the HYCAT Investigator Group: Serial prostate specific antigen (PSA) measurements in patients with clinical benign prostatic hyperplasia (BPH) enrolled in a randomized, double-blinded, placebo-controlled study with terazosin (abstract). J Urol 153 (suppl): 396A, 1995.
18. Waldstreicher J., Tocker P.F., Cheng J., et al. The effects of finasteride on serum prostate specific antigen (PSA) in men with benign prostatic hyperplasia (abstract). J Urol. 153:(suppl):1995;396A.
19. 1A-adrenoceptor antagonist a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH) . Eur Urol. 29:1996;155-167.
20. Schulman C.C., Cortvriend J., Jonas U., et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH) . Eur Urol. 29:1996;145-154.
21. 1C-adrenoceptor antagonist a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH) . Br J Urol. 76:1995;325-336.